Roy S, Hemsell D, Gordon S, Godwin D, Pearlman M, Luke D
Department of Obstetrics and Gynecology, University of Southern California School of Medicine and Women's and Children's Hospital, Los Angeles 90033, USA.
Am J Surg. 1998 Dec;176(6A Suppl):62S-66S. doi: 10.1016/s0002-9610(98)00222-0.
Trovafloxacin is a new fourth-generation fluoroquinolone whose pharmacokinetics and in vitro activity suggest that it is well suited for antibiotic prophylaxis in elective hysterectomy.
In a randomized, double-blind, multicenter study, parallel groups of women 18 years of age or older received either 200 mg trovafloxacin by mouth and intravenous (i.v.) placebo or 2 g cefoxitin by i.v. infusion and placebo by mouth before elective vaginal or abdominal hysterectomy for nonmalignant disease.
In the 103 and 97 patients in the trovafloxacin and cefoxitin groups, respectively, who were evaluable for efficacy, the prophylactic success rates at hospital discharge (96% in both groups) and 30 +/- 6 days after hysterectomy (88% and 91% in the trovafloxacin and cefoxitin groups, respectively) were statistically equivalent. Both antibiotics were well tolerated.
A single oral 200 mg dose of trovafloxacin is as effective and safe as a standard cefoxitin parenteral regimen in the prevention of primary bacterial infection after elective vaginal or abdominal hysterectomy for nonmalignant disease.
曲伐沙星是一种新型的第四代氟喹诺酮类药物，其药代动力学和体外活性表明它非常适合用于择期子宫切除术中的抗生素预防。
在一项随机、双盲、多中心研究中，18岁及以上的女性平行分组，在择期阴道或腹部子宫切除治疗非恶性疾病前，一组口服200mg曲伐沙星并静脉注射安慰剂，另一组静脉输注2g头孢西丁并口服安慰剂。
分别在曲伐沙星组和头孢西丁组中可评估疗效的103例和97例患者中，出院时的预防成功率（两组均为96%）以及子宫切除术后30±6天的预防成功率（曲伐沙星组和头孢西丁组分别为88%和91%）在统计学上相当。两种抗生素耐受性均良好。
对于非恶性疾病择期阴道或腹部子宫切除术后预防原发性细菌感染，单次口服200mg曲伐沙星与标准的头孢西丁胃肠外给药方案同样有效且安全。
